Global Hospital-Acquired Disease Testing Market, by Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus (MRSA), and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is expected to be valued at US$ 925.4 million in 2019, and is expected to exhibit a CAGR of 20.0% over the forecast period (2019-2027), as highlighted in a new report published by Coherent Market Insights.
Manufacturers are focusing on launches and approvals of innovative and advanced testing kits in order to enhance the diagnosis of hospital-acquired diseases which is expected to drive the market growth during the forecast period. For instance, in November 2018, Biomérieux received 510K clearance from the U.S. Food and Drug Administration (FDA) for BIOFIRE FILMARRAY Pneumonia Panel which would help in the diagnosis of lower respiratory tract infections. The BIOFIRE FILMARRAY Pneumonia Panel is designed to identify 33 targets which include 18 bacteria, 8 viruses, and 7 antimicrobial resistance genes.
Similarly, in October 2018, GenePOC, a subsidiary of Debiopharm Group, launched GenePOC CDiff assay which is to be used with the revogene instrument. The assay is a qualitative in-vitro diagnostic test to detect the toxin B (tcdB) gene of toxigenic C. difficile in patients with C. difficile infection.
Browse 33 Market Data Tables and 30 Figures spread through 140 Pages and in-depth TOC on “Hospital-acquired Disease Testing Market”- Global Forecast to 2027, by Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia Stents, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus (MRSA), and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the global hospital-acquired disease testing market, click the link below:
https://www.coherentmarketinsights.com/market-insight/hospital-acquired-disease-testing-market-992
An increasing number of government initiatives to control and prevent hospital-acquired infections are expected to boost the growth of the hospital-acquired disease testing market over the forecast period. For instance, in November 2019, The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services (HHS), entered an agreement with Inflammatix Inc. to support the advanced development of host-response testing technology. Under the agreement Inflammatix Inc. received financial and technical support from Biomedical Advanced Research and Development Authority (BARDA) to develop three rapid diagnostics tests which can distinguish bacterial infections from viral infections by reading gene expression patterns in the immune system.
Key Takeaways of the Global Hospital-acquired Disease Testing Market:
- The global hospital-acquired disease testing market is expected to exhibit a CAGR of 20.0% over the forecast period owing to rising incidence of hospital-acquired diseases, and approvals and launches of products. According to the House of Commons Library, UK Parliament, around 4,650 cases of clostridium difficile (c. diff) Infection were reported in the National Health Service hospitals in England in year 2017.
- Among test type, urinary tract infection segment held a significant market share in 2018 owing to increasing incidence of urinary tract infections. According to the World Health Organization, 2018, urinary tract infections accounted for 40% of all the hospital acquired infections.
- Companies operating in the global hospital-acquired disease testing market include Luminex Corporation, Diatherix Laboratories, Life Technologies, Cantel Medical Corporation, Meridian Biosciences Inc, Nordion Inc, Qiagen GmbH, F.Hoffmann-La Roche Ltd., Biomérieux, and Cepheid.
